KaydedilenlerDerginizi ekleyin

Dergiler / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 4

Comparison of Intravitreal Afl ibercept and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Retina Ven Dal Tıkanıklığına Sekonder Gelişen Makula Ödeminde İntravitreal Afl ibercept ve Ranibizumab Karşılaştırması

Faruk KAYA
İbrahim KOÇAK
Ali AYDIN
Hakan BAYBORA
Hacı KOÇ
YUNUS KARABELA
Sayfa
323–327
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There were no signifi cant differences between two groups at month 12, including fi nal BCVA, changes in BCVA, fi nal CMT, and changes in CMT (p> 0.05) Conclusion: Afl ibercept presented similar decrease in CMT and improvement in BCVA with lesser number of injections for macular edema due to BRVO.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: To compare the effi cacy of intravitreal injection of ranibizumab and afl ibercept on the treatment of macular edema due to branch retinal vein occlusion (BRVO).
📊
Temel Bulgular & Veri:Materials and Methods: In this retrospective study; eyes with macular edema secondary to BRVO which treated with intravitreal ranibi- zumab (IVR) or afl ibercept( IVA) and followed at least 12 months between September 2012 and March 2016 were reviewed.
💡
Sonuç & Katkı:There were no signifi cant differences between two groups at month 12, including fi nal BCVA, changes in BCVA, fi nal CMT, and changes in CMT (p> 0.05) Conclusion: Afl ibercept presented similar decrease in CMT and improvement in BCVA with lesser number of injections for macular edema due to BRVO.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2012 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Purpose: To compare the effi cacy of intravitreal injection of ranibizumab and afl ibercept on the treatment of macular edema due to branch retinal vein occlusion (BRVO). Materials and Methods: In this retrospective study; eyes with macular edema secondary to BRVO which treated with intravitreal ranibi- zumab (IVR) or afl ibercept( IVA) and followed at least 12 months between September 2012 and March 2016 were reviewed. Mean number of injections and changes in two groups’ best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by optical coherence tomography at month 1, 3, 6 and 12 were reviewed and compared. Results: Mean BCVA improved signifi cantly in IVR group (p=0.03, 0.04, 0.02 and 0.03 respectively) and IVA group (p=0.02, 0.04, 0.03 and 0.03 respectively ; and CMT decreased signifi cantly in IVR group (p=0.02, 0.02, 0.02 and 0.03 respectively) and IVA group (p=0.001, 0.03, 0.01 and 0.02 respectively) at 1, 3, 6 and 12th months. Mean number of injections per eye within twelve months were 3.4±1.2 in rani- bizumab group, and 2.2±1.1 in afl ibercept group (p=0.03). There were no signifi cant differences between two groups at month 12, including fi nal BCVA, changes in BCVA, fi nal CMT, and changes in CMT (p> 0.05) Conclusion: Afl ibercept presented similar decrease in CMT and improvement in BCVA with lesser number of injections for macular edema due to BRVO.

Abstract

Amaç: Retina ven dal tıkanıklığına (RVDT) sekonder gelişen macula ödeminde intravitreal ranibizumab ve afl ibercept enjeksiyonunun etkinliğinin karşılaştırılması. Gereç ve Yöntemler: Retrospektif çalışmamızda Eylül 2012 ve Mart 2016 arasında RVDT’na sekonder gelişen macula ödemi için intra- vitreal ranibizumab (IVR) ve afl ibercept (IVA) enjeksiyonu uygulanmış ve az 12 ay takip edilmiş hastalar değerlendirildi Ortalama enjek- siyon sayısı, iki grup arasındaki 1,3,6 ve 12. aylarda ölçülenen en iyi düzeltilmiş görme keskinliği (EDGK) ve optic koherens tomografi de ölçülmüş santral maküler kalınlık (SMK) farkları değerlendirildi ve karşılaştırıldı. Bulgular: 1, 3, 6 ve 12. aylarda ortalama EDGK; IVR (sırasıyla p=0.03, 0.04, 0.02 ve 0.03) ve IVA grubunda (sırasıyla p=0.02, 0.04, 0.03 ve 0.03) anlamlı olarak artarken SMK; IVR (sırasıyla p=0.02, 0.02, 0.02 ve 0.03) ve IVA grubunda (sırasıyla p=0.001, 0.03, 0.01 ve 0.02) anlamlı olarak azaldı. 12 ay sonunda ortalama enjeksiyon sayısı ranibizumab grubunda 3.4±1.2, afl ibercept grubunda 2.2±1.1 oldu (p=0.03). 12 ay sonunda iki grup arasında son EDGK, EDGK değişimi, son SMK ve SMK değişimi açısından anlamlı fark yoktu (p> 0.05). Sonuç: RVDT’na bağlı macula ödeminde afl ibercept daha az enjeksiyon sayısı ile ranibizumaba benzer şekilde SMK’da azalma ve ED- GK’da artış sunmuştur.

🔖

Bu Makaleye Atıf Yap

KAYA, F., KOÇAK, İ., AYDIN, A., BAYBORA, H., KOÇ, H., KARABELA, Y. (2018). Comparison of Intravitreal Afl ibercept and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. Retina-Vitreus, Cilt: 27 - Sayı: 4, 323–327. https://ajindex.com/articles/308121

Kaynakça (11)

  1. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlu- sion. Curr Opin Ophthalmol 2012;23(3):175-81 The EyeDisease Case Control Study Group. Risk factors for central and branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-96
  2. H Noma, H Funatsu, M Yamasaki et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22:42-8
  3. Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Oph- thalmol 2005;140(2):256-61
  4. Noma H, Minamoto A, Funatsu H et al. Intravitreal levels of vas- cular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244(3):309-15
  5. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability fac- tor, an endothelial cell mitogen related to PDGF. Science 1989;246(4935):1309-12
  6. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothe- lial growth factor is a secreted angiogenic mitogen. Science 1989;246(4935):1306-9
  7. Campochiaro PA, Hafi z G, Shah SM, et al.Ranibizumab for mac- ular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16(4):791-9
  8. Rouvas A, Petrou P, Ntouraki A, et al. Intravitreal ranibizumab (Lu- centis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Retina 2010;30(6):893- 902 Fauser S, Schwabecker V, Muether PS. Suppression of intraoc- ular vascular endothelial growth factor during afl ibercept treat- ment of age-related macular degeneration. Am J Ophthalmol 2014;158(3):532-6
  9. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal afl iber- cept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 2005;122(3):538-44
  10. Yuan A, Ahmad BU, Xu D, et al. Comparison of intravitre- al ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol 2014;18;7(1):86-91 The Branch Vein Occlusion Study Group. Argon laser photocoagu- lation for macular edema in branch vein occlusion. Am J Ophthal- mol 1984;98(3):271-82 Stefánsson E.Treatment of branch retinal vein occlusion. Acta Ophthalmol 2008;86:122-3
  11. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal